Kiniksa Pharmaceuticals, Ltd.KNSANASDAQ
Loading
EV/EBITDA Over TimeExpanding
Percentile Rank89
3Y CAGR-24.9%
Studio
Year-over-Year Change

Enterprise value to EBITDA ratio

3Y CAGR
-24.9%/yr
Annual compound
Percentile
P89
Within normal range
vs 3Y Ago
0.4x
Contraction
Streak
2 yr
Consecutive growthExpanding
PeriodValueYoY Change
202532.12+213.9%
2024-28.21+43.1%
2023-49.58-165.4%
202275.77+1792.5%
2021-4.48+30.8%
2020-6.47-87.7%
2019-3.45+28.9%
2018-4.85+46.0%
2017-8.97+62.7%
2016-24.03-